Strengthening the Management Foundation of the Animal Health Products and Food Processing Ingredients Businesses
First written in FY2016. 17 of 25 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「We will strengthen sales in Japan and overseas centered on polysaccharides, the main product of MP五協フード＆ケミカル株式会社 (Kita-ku, Osaka). In the chemicals field, we will seek to increase earnings by strengthening customer services through efforts to establish systems and develop products to accelerate the expansion of our electronic chemicals business for the semiconductor market.」
In the food-processing raw materials and chemicals fields, efforts are under way to increase earnings through polysaccharides, electronic chemicals for semiconductors, product development and the restructuring of the sales organization. - FY2026-H1AdvancedAnnual report
「Sales increased by ¥6 million, or 0.0%, from the same period of the previous year to ¥58,613 million.」
While sales in the veterinary pharmaceuticals, food-processing raw materials wholesale and related businesses increased only 0.0% year on year, operating profit rose 15.8% to ¥1,353 million. In veterinary pharmaceuticals, results benefited from an expansion in trading partners among manufacturers, the introduction of new products, and demand for aquaculture vaccines and cattle feed ingredients, while the chemicals field expanded in food-processing raw materials. - FY2025Veterinary pharmaceuticals: higher sales, lower profit; food ingredients strongAnnual report
「In the companion-animal field of the veterinary pharmaceuticals and related wholesale business, performance remained firm, supported by the proactive introduction of new products and other initiatives, despite the impact of a change in distribution channels under which certain pet foods began to be sold directly by manufacturers. In the livestock and aquatic-products fields, performance remained firm, supported by special demand for products related to avian influenza outbreaks and expanded sales of functional products that contribute to higher productivity. In the food-processing raw materials wholesale and related businesses, sales in the food ingredients and chemicals fields remained strong, resulting in higher sales for the segment as a whole.」
Sales of veterinary pharmaceuticals remained firm on new products and functional products, but segment operating profit was ¥2,444 million, down 10.4% from the previous fiscal year. Food ingredients and chemicals performed strongly, and the segment as a whole posted higher sales. - FY2025-H1Veterinary pharmaceuticals sluggish; food ingredients strongAnnual report
「The veterinary pharmaceuticals and related wholesale business faced a difficult environment. Although the companion-animal business remained firm despite the impact of a change in distribution channels under which certain pet foods began to be sold directly by manufacturers, demand for pharmaceuticals and other products in the livestock business declined as feed prices soared due to the weaker yen, and sales of products related to avian influenza, which had arisen in the previous corresponding period, decreased. Meanwhile, in the food-processing raw materials wholesale and related businesses, market conditions for food ingredients were strong, the market for industrial chemicals in the chemicals field showed signs of recovery, and sales of cosmetic raw materials remained strong. As a result, total segment sales increased.」
While demand for veterinary pharmaceuticals declined in the livestock business and sales of products related to avian influenza decreased, sales of food ingredients, industrial chemicals and cosmetic raw materials were strong. - FY2024AdvancedAnnual report
「In November 2023, we entered into a basic agreement concerning the integration of MP五協Ｆ＆Ｃ and メディパルフーズ株式会社 (Chuo-ku, Sapporo; hereinafter, “メディパルフーズ”).」
To strengthen the operating base in the food-processing raw materials and chemicals fields, a basic agreement was reached concerning the integration of MP五協F&C and メディパルフーズ, with completion of the integration scheduled for 1 October 2024. - FY2024-Q3AdvancedAnnual report
「In veterinary pharmaceuticals in the existing businesses, the poultry and swine markets recovered, while pharmaceuticals for companion animals (*) also remained firm. Sales of food-processing raw materials in the existing businesses increased as a result of reviews of selling prices in response to soaring raw material costs, the recovery of the food market following the reclassification of COVID-19 as a Class 5 infectious disease, and the expansion of new business relationships.」
In the veterinary pharmaceuticals, food-processing raw materials wholesale and related businesses, results benefited from the consolidation of MP五協F&C, the recovery of the poultry and swine markets, firm performance in companion-animal pharmaceuticals, reviews of selling prices, the recovery of the food market, and the expansion of new business relationships. Segment sales increased 54.1% year on year, while operating profit increased 5.1%. - FY2024-Q1AdvancedAnnual report
「Sales increased by ¥10,326 million, or 55.7%, from the same period of the previous year to ¥28,875 million. Operating income increased by ¥139 million, or 20.2%, from the same period of the previous year to ¥831 million.」
In the animal pharmaceuticals, food processing ingredients and related businesses, sales increased substantially following the consolidation of MP Gokyo Food & Chemical, with the recovery of the food market and price increases associated with soaring raw material costs also contributing. Operating income also increased year on year. - FY2023-Q3Weak sales due to avian influenza and higher costsAnnual report
「Although the Company promoted the adoption and establishment of its proprietary products, expanded use of its proprietary WEB ordering information system for veterinary hospitals, MP+, and a new sales model combining distribution and marketing functions, sales were somewhat sluggish due to the impact of avian influenza, which was spreading at an unprecedented rate, and soaring production costs.」
While promoting expanded use of MP+ and a new sales model, sales of animal pharmaceuticals were somewhat sluggish due to the spread of avian influenza and soaring production costs. - FY2021AdvancedAnnual report
「As a result, sales in the wholesale business for animal pharmaceuticals, food processing ingredients and related products were ¥69,146 million, up 1.1% year on year, and operating income was ¥2,309 million, up 16.7%.」
In the animal pharmaceuticals and food processing ingredients businesses, sales and operating income increased year on year, driven by expanded use of MP+, business continuity measures and expanded new transactions, among other factors. - FY2021-Q2RestatedAnnual report
「Sales of animal pharmaceuticals progressed steadily due to expanded use of the Company's proprietary WEB ordering information system for veterinary hospitals, MP+. As COVID-19 infections spread, the Company implemented measures necessary to continue operations and maintain stable supply, including thorough hygiene management at branches and logistics centers, voluntarily suspending visits and taking orders through telework.」
In the animal pharmaceuticals and food processing ingredients businesses, the Company continues measures to maintain business continuity, including expanded use of MP+, stable supply, hygiene management, voluntarily suspending visits and taking orders through telework. - FY2021-Q1AdvancedAnnual report
「Sales of animal pharmaceuticals progressed steadily due to expanded use of the Company's proprietary WEB ordering information system for veterinary hospitals, MP+. As COVID-19 infections spread, the Company implemented measures necessary to continue operations and maintain stable supply, including thorough hygiene management at logistics centers, voluntarily suspending visits and taking orders through telework. As a result, sales in the wholesale business for animal pharmaceuticals, food processing ingredients and related products were ¥17,257 million, down 0.3% year on year, and operating income was ¥649 million, up 16.5%.」
In addition to expanded use of MP+, the Company implemented thorough hygiene management, voluntarily suspended visits and accepted orders through telework. Segment operating income increased 16.5% year on year. - FY2020AdvancedAnnual report
「As a result, sales in the wholesale business for animal pharmaceuticals, food processing ingredients and related products were ¥68,405 million, up 3.3% year on year, and operating income was ¥1,979 million, up 23.1%.」
In the animal pharmaceuticals and food processing ingredients businesses, full-year sales were ¥68,405 million and operating income was ¥1,979 million, driven by expanded use of MP+, proprietary products and new transactions through proposal-based sales. - FY2020-Q3AdvancedAnnual report
「Sales of animal pharmaceuticals progressed steadily, supported by proactive efforts focused on vaccines and feed additives in the livestock market, expanded use of the Company's proprietary WEB ordering information system for veterinary hospitals, MP+, and efforts involving proprietary products in the companion-animal market. Sales of food processing ingredients progressed steadily as new transactions expanded through the promotion of proposal-based sales. As a result, sales in the wholesale business for animal pharmaceuticals, food processing ingredients and related products were ¥52,564 million, up 3.5% year on year, and operating income was ¥1,646 million, up 18.6%.」
The Company reported expanded use of MP+ and proprietary products in animal pharmaceuticals, and expanded new transactions in food processing ingredients. Segment sales and operating income also increased year on year. - FY2020-Q2AdvancedAnnual report
「Sales of animal pharmaceuticals progressed smoothly, supported by proactive efforts focused on vaccines and feed additives in the livestock market, expanded use of the Company's proprietary WEB ordering information system for veterinary hospitals, MP+, and efforts involving proprietary products in the companion-animal market. Sales of food processing ingredients progressed smoothly as new transactions expanded through the promotion of proposal-based sales. As a result, sales in the wholesale business for animal pharmaceuticals, food processing ingredients and related products were ¥35,065 million, up 6.6% year on year, and operating income was ¥1,124 million, up 35.5%.」
The Company reported expanded use of MP+, proprietary products and new transactions in food processing ingredients, along with year-on-year increases in segment sales and operating income. - FY2019-Q3RestatedAnnual report
「Sales of animal pharmaceuticals progressed smoothly, supported by proactive efforts focused on vaccines and feed additives in the livestock market, expanded use of the Company's proprietary WEB ordering information system for veterinary hospitals, MP+, and exclusive sales of skincare products in the companion-animal market. Sales of food processing ingredients progressed smoothly as transactions with major customers expanded through the promotion of proposal-based sales.」
In animal pharmaceuticals, the Company pursued vaccines and feed additives, MP+ and exclusive skincare products, while continuing to expand transactions with major customers through proposal-based sales of food processing ingredients. - FY2019-Q2AdvancedAnnual report
「Sales of animal pharmaceuticals progressed smoothly, supported by proactive efforts focused on vaccines and feed additives in the livestock market, expanded use of the Company's proprietary WEB ordering information system for veterinary hospitals, MP+, and efforts involving exclusive skincare products in the companion-animal market. The Company also strengthened its distribution system by establishing a logistics center in the Kanto area, the largest domestic market. Sales of food processing ingredients progressed smoothly as transactions with major customers expanded through the promotion of proposal-based sales.」
In animal pharmaceuticals, the Company expanded use of MP+, promoted exclusive skincare products and strengthened efforts in the Kanto area, where it established a logistics center. In food processing ingredients, transactions with major customers expanded through proposal-based sales. - FY2019-Q1RestatedAnnual report
「Sales of animal pharmaceuticals progressed steadily, supported by proactive efforts focused on vaccines and feed additives in the livestock market, stronger efforts in the Kanto area, the largest domestic market, for companion animals, and expanded use of the Company's proprietary WEB ordering information system for veterinary hospitals, MP+®. Sales of food processing ingredients and related products progressed smoothly as transactions with major customers increased through the promotion of proposal-based sales and expansion of product procurement routes.」
The Company continues to pursue vaccines and feed additives, the Kanto area and MP+ in animal pharmaceuticals, while promoting proposal-based sales and expanding procurement routes for food processing ingredients. - FY2018AdvancedAnnual report
「As a result, sales in the wholesale business for animal pharmaceuticals, food processing ingredients and related products were ¥63,093 million, up 5.6% year on year, and operating income was ¥1,513 million, up 31.5%.」
In animal pharmaceuticals, the Company pursued vaccines and feed additives as well as treatments for skin diseases, while in food processing ingredients it pursued proposal-based sales and transactions with major customers, resulting in higher sales and operating income. - FY2018-Q3AdvancedAnnual report
「Sales of animal pharmaceuticals progressed smoothly, supported by proactive efforts focused on vaccines and feed additives in the livestock market, growth in treatments for skin diseases and aging-related products in the companion-animal market, and expanded use of the Company's proprietary WEB ordering information system for veterinary hospitals, MP+®. Sales of food processing ingredients also progressed smoothly as transactions with major customers expanded through proposal-based sales. As a result, sales in the wholesale business for animal pharmaceuticals, food processing ingredients and related products were ¥48,376 million, up 6.3% year on year, and operating income was ¥1,296 million, up 31.1%.」
In animal pharmaceuticals, efforts advanced in vaccines and feed additives, treatments for skin diseases and aging-related products, while transactions with major customers expanded in food processing ingredients through proposal-based sales. Segment sales and operating income also increased year on year. - FY2018-Q2AdvancedAnnual report
「Sales of animal pharmaceuticals progressed smoothly, supported by growth in products for skin diseases and aging-related conditions in the companion-animal market and expanded use of the Company's proprietary WEB ordering information system for veterinary hospitals, MP+®. As a result, sales in the wholesale business for animal pharmaceuticals, food processing ingredients and related products were ¥31,546 million, up 5.6% year on year, and operating income was ¥779 million, up 22.1%.」
Expanded use of the WEB ordering system for veterinary hospitals and growth in animal pharmaceutical products contributed to year-on-year increases in segment sales and operating income. - FY2017AdvancedAnnual report
「Sales in the wholesale business for animal pharmaceuticals, food processing ingredients and related products were ¥59,762 million, up 26.7% year on year, and operating income was ¥1,150 million, up 23.9%.」
In the animal pharmaceuticals and food processing ingredients businesses, sales and operating income increased year on year, driven by procurement and sales routes expanded nationwide and efforts focused on priority products. - FY2017-Q3AdvancedAnnual report
「Sales of animal pharmaceuticals progressed smoothly, supported by proactive efforts with feed additives in the livestock market, which help prevent livestock diseases and improve meat quality, and by a focus on treatments for skin diseases and products related to aging in the companion-animal market. Sales of food processing ingredients and related products also progressed smoothly as procurement routes and sales channels expanded nationwide.」
In animal pharmaceuticals, efforts expanded to feed additives and treatments for skin diseases and aging-related conditions, while in food processing ingredients, procurement routes and sales channels expanded nationwide. - FY2017-Q2RestatedAnnual report
「Sales of food processing ingredients and related products progressed smoothly, supported by efforts to propose a broad range of products by leveraging nationwide information and procurement routes.」
The food processing ingredients business continues to propose products using nationwide information and procurement routes. - FY2017-Q1AdvancedAnnual report
「Following the launch of メディパルフーズ株式会社 and its inclusion as a consolidated subsidiary, the segment name was changed from the wholesale business for animal pharmaceuticals and related products to the “wholesale business for animal pharmaceuticals, food processing ingredients and related products” beginning with the current consolidated fiscal year. Sales of food processing ingredients and related products progressed smoothly, supported by efforts to capitalize on the benefits of integrating the food business and to propose a broad range of products and develop sales channels using nationwide information and procurement routes.」
The food processing ingredients business was launched as メディパルフーズ and made a consolidated subsidiary, advancing product proposals and sales-channel development by leveraging the benefits of integrating the food business and nationwide information and procurement routes. - FY2016First statedAnnual report
「With an eye to future changes in the market environment for each of the animal pharmaceuticals and food businesses, we will work to strengthen our management platform and enhance customer services.」
The Company is addressing the animal pharmaceuticals and food businesses separately and advancing efforts to strengthen the platform and improve customer services in each.